Hugel's Record-Breaking Financial Performance in 2024: A Deep Dive

In the third quarter of 2024, Hugel, a leading global medical aesthetics company, reported record-breaking financial results, with net sales of KRW105.1 billion, operating profit of KRW53.4 billion, and net income of KRW42 billion. This remarkable performance was driven by several key factors, including the company's global expansion strategy, strong performance in botulinum toxin and hyaluronic acid fillers, and the success of its cosmetics brands.

Hugel's global expansion strategy has been a significant driver of its financial success. The company's overseas sales of botulinum toxin jumped 73% on-year in the third quarter, with robust growth in the Asia-Pacific region and initial shipments to the US market. In the US, Hugel plans to officially launch its botulinum toxin, Botulax, later in 2024 through collaborations with its California-based partner, BENEV Company Inc. This strategic move aims to achieve around 10% share in the US market within three years.



The strong performance of botulinum toxin and hyaluronic acid fillers has also contributed to Hugel's record-breaking financial results. Sales of botulinum toxin "Botulax" rose 41% on-year to reach KRW64.7 billion, driven by overseas sales growth and positive responses for 300 IU in the domestic market. The toxin's overseas sales jumped 73% in the third quarter on-year, thanks to the initial shipment to the US and robust growth from the Asia-Pacific market. Sales of hyaluronic acid (HA) fillers THE CHAEUM and BYRYZN SKINBOOSTER HA amounted to KRW29.9 billion in the third quarter, with steady growth across global markets, including a 7% year-over-year increase in Europe.

Hugel's cosmetics brands, such as WELLAGE and BYRYZN BR, also posted a 37.4% rise in sales year-over-year. Derma cosmetics brand WELLAGE released a new lineup, Hyper Peptide, in August 2023, contributing to a 35% sales growth. High-end cosmetics brand BYRYZN BR has been increasing its consumer base since its market debut in April 2023. Additionally, the company's bioabsorbable suture BlueRose is also strengthening its growth.

To maintain its competitive edge in botulinum toxin and hyaluronic acid fillers, and explore new opportunities for growth, Hugel can consider the following strategies:

1. Strengthen Global Expansion: Hugel should continue to expand its sales networks and increase its market share in global markets, particularly in the US and Asia-Pacific regions.
2. Diversify Product Portfolio: While botulinum toxin and hyaluronic acid fillers are core products, Hugel can explore new opportunities by developing new product lines or entering new markets, such as cosmetics or other medical aesthetics products.
3. Invest in R&D and Innovation: Hugel should continue to invest in research and development to maintain its technological edge and introduce new products that meet evolving consumer needs.
4. Strengthen Brand Value and Assets: Hugel should focus on enhancing its brand value and assets in new markets to build customer loyalty and increase market share.
5. Leverage Strategic Partnerships: Hugel can form strategic partnerships with local companies or distributors to expand its reach and strengthen its position in new markets.

By implementing these strategies, Hugel can maintain its competitive edge in botulinum toxin and hyaluronic acid fillers while exploring new opportunities for growth. The company's record-breaking financial performance in 2024 serves as a testament to its successful global expansion strategy and strong product offerings. As Hugel continues to adapt and innovate, it is well-positioned to capitalize on the growing demand for medical aesthetics products and services.

Word count: 598